Mortality and morbidity of dialysis patients
long-term effects of normalized haematocrit values in uraemic patients have not been exhaustively evaluated The major aims of dialysis therapy consist in proin prospective randomized multicentre studies. Therelonging patients' survival, reducing the patients morfore the question arises as to what extent anaemia bidity and improving their quality of life. However should be corrected in order to avoid undesirable despite many technical advances in the medical care side-effects. and in the delivery of dialysis over the past years, mortality and morbidity of dialysis patients remains persistently high and their quality of life is rather poor. The Japanese data A Japanese retrospective study [6 ] , analysing a total
Anaemia as cardiovascular risk factor
of 2116 patients has reported that the administration of rHuEpo might be responsible for an increased risk Hypertension and anaemia play a pivotal role in the of cardiovascular disease (especially stroke and acute increased mortality and morbidity in uremic patients myocardial infarction), although only a trend towards and should be managed appropriately. In fact anaemia an increase in the incidence of stroke and acute has been found to be an independent risk factor for myocardial infarction was noted. However, some relevdeveloping cardiac morbidity and mortality in dialysis ant methodological drawbacks were underlined [7, 8] . patients [1, 2] and cardiovascular disease is the major This study prompted us to further clarify this important cause of death in these patients. It is well known that aspect. We performed a historical prospective study cardiac hypertrophy is very frequent in dialysis patients concerning the clinical effects of the use of rHuEpo in and anaemia and hypertension are very important risk patients dialysed in Lombardy. The study aimed at factors in this complication, clearly related to the clarifying the clinical impact of anaemia and rHuEpo cardiovascular mortality, as anaemia is accompanied treatment on general and cardiovascular mortality and by an increase of cardiac work that induces left morbidity. ventricular hypertrophy. Of course other factors are important in inducing left ventricular hypertrophy, as arteriovenous fistula and, among other hormones, The Lombardy data
Lombardy is a region of Northern Italy with 8 910 451 inhabitants (31 December 1994). It has a registry for Importance of correcting anaemia end-stage renal disease ( ESRD) patients with a 100% response rate from the 44 Lombardy dialysis units). A reduction of cardiac hypertrophy by controlling A detailed study of Lombardy 1983 to 1992 dialysis hypertension and correcting anaemia in dialysis and transplantation results has been reported elsewhere patients has been demonstrated [4, 5] . The improve- [9] . The Lombardy Registry is permitted to track the ment of anaemia by erythropoietin (rHuEpo) is accommodality of treatment and the outcome of ESRD panied by beneficial effects; however, opposing the patients alive at 1 January 1983 and of the incident changes advantageous for uraemic patients are the patients with ESRD from the same date. In order to address the above-mentioned clinical questions, we were evaluated: (i) all-cause mortality, (ii) cardio-rHuEpo and 15.2% in those not so treated. Figure 2 shows the overall crude mortality of the patients strativascular mortality, (iii) cerebrovascular mortality, and (iv) cerebrovascular morbidity. The relationship fied according to three levels of haematocrit (haematocrit <27%: 887 patients, 27-32%: 2043 patients, between the outcome during the calendar year 1996 and haematocrit levels with or without rHuEpo >32%: 1498 patients respectively). The crude odds ratio associated with the prescription of rHuEpo was therapy was adjusted for the age at the beginning of renal replacement therapy (RRT ), gender, presence of 0.70. Adjusting for known risk factors such as age at the beginning of RRT, gender, time on dialysis treatcomorbid conditions as of 31 December 1995, modality of treatment, and time spent on dialysis treatment ment, comorbid conditions, and haematocrit level on 31 December 1995, yielded an odds ratio of 0.65 (95% before 31 December 1995.
On 31 December 1995, 5302 patients were on dialysis c.i. 0.52-0.81, P<0.001). If one treats haematocrit levels, spontaneous or because of rHuEpo treatment, treatment in Lombardy. The main characteristics of this population are reported in Table 1 . The mean as continuous variables, the mean risk of all-causes mortality decreases with increasing haematocrit levels haematocrit of the patients was 30.1±4.5%, and 70.7% of them had been treated with rHuEpo. Figure 1 shows (odds ratio: 0.95 per unit of haematocrit, 95% confidence interval 0.92-0.97). Taking only cardiovascular the distribution of the patients according to haematocrit level.
mortality as an end-point and using the same model, 3.4% of the patients on rHuEpo therapy in 1996 died As far as general mortality is concerned, the frequency of death observed in this population during from cardiovascular causes in comparison to 5.6% in those untreated patients (crude odds ratio 0.59). the calendar year 1996 was 11.1% in those treated with pected benefit from the rHuEpo therapy per se, on allcauses of mortality at least partly independent of the effect on haematocrit levels. However, it should be pointed out that the model for all-causes mortality, even though its prediction rate was generally good +(88%), failed to predict correctly the events (5%). Consequently, we are not able to clearly establish that rHuEpo has some pharmacological effect not depending on the anaemia correction. In any case, the negative findings reported by Iseki et al. [6 ] in Japanese patients are not confirmed by the data of the Lombardy registry.
Conclusion
Adjusting and using the above-mentioned statistical model, the odds ratio did not change significantly Higher levels of haematocrit, either spontaneously (odds ratio: 0.61, 95% confidence interval 0.43-0.86, achieved or resulting from rHuEpo treatment, improve P<0.05). Figure 2 shows similar crude cardiovascular outcome parameters of dialysis patients. According to mortality at the three levels of haematocrit: when the data of the Lombardy registry, rHuEpo therapy considering the whole set of predictors, the analysis seems to protect against overall and cardiovascular confirmed the absence of any statistical association mortality and morbidity. between haematocrit (continuous variable) and cardiovascular mortality. The same analysis performed with the death from cerebrovascular cause as end-point
